RAS inhibition: a game changer in pancreatic cancer?
Preclinical findings show antitumour activity of triple KRAS inhibition in mouse models, but it will take years of rigorous research to assess its clinical efficacy in oncology patients
Novel combination shows survival benefits in high-risk gastric/gastro-oesophageal junction cancer
Encouraging data were reported for SHR-1701 added to first-line CAPOX in a post-hoc analysis of patients with high-risk features from a Chinese study
Is there still a role for anti-TIGIT therapy in hepatocellular carcinoma?
While the IMbrave152/SKYSCRAPER-14 trial showed no added benefit with tiragolumab, other studies are ongoing to explore the potential of additional immune checkpoint inhibition in combination with standard therapy
First-line bemarituzumab improves short-term survival in gastric or gastroesophageal junction cancer overexpressing FGFR2b
Positive initial overall survival data were, however, attenuated and may not be clinically meaningful in a longer-term analysis
First-in-human trial of a TCR-T therapy targeting KRAS G12V reports a significant response rate
Preliminary results of NW-301V are promising, with a lack of severe adverse effects at all doses tested in patients with pancreatic cancer or colorectal cancer
Research in pancreatic adenocarcinoma targets antibody-drug conjugates and oncolytic viruses
While telisotuzumab adizutecan demonstrated early antitumour activity, only modest benefits were seen with VCN-01 added to standard care
Novel immunotherapy combinations address unmet needs in liver cancers
Potentially practice-changing data were presented for atezolizumab plus bevacizumab, and camrelizumab plus rivoceranib in hepatocellular carcinoma
The long road toward treatment personalisation for pancreatic and rectal cancers
The 2025 ESMO Awardee, Thierry Conroy, traces the major advances in the field while noting that several barriers to improving patient outcomes remain
Data supports the use of an electric-based therapy combined to standard treatment in locally advanced pancreatic adenocarcinoma
Quality of life and pain management data adds to efficacy results of combining TTFields with gemcitabine and nab-paclitaxel as a potential new option of care
Promising activity reported for olaparib in advanced biliary tract cancers
Study indicates that PARP inhibition could extend treatment options for patients with biliary tract cancers